Skip to Content
Merck
CN
All Photos(2)

Documents

Safety Information

HIGFBMAG-53K

Millipore

MILLIPLEX® Human IGF Binding Protein Magnetic Bead Panel - Metabolism Multiplex Assay

The Human IGF Binding Protein Panel, using the Luminex xMAP technology, enables the simultaneous analysis of 7 IGFBP protein biomarkers in human serum, plasma and cell culture samples.

Sign Into View Organizational & Contract Pricing
All Photos(2)
UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Quality Level

200

species reactivity

human

manufacturer/tradename

Milliplex®

assay range

accuracy: 79%
(IGFBP-5)
sensitivity: 0.01 ng/mL
(MinDC+2SD; IGFBP-1)
sensitivity: 0.07 ng/mL
(MinDC+2SD; IGFBP-7)
sensitivity: 0.12 ng/mL
(MinDC+2SD; IGFBP-6)
sensitivity: 0.15 ng/mL
(MinDC+2SD; IGFBP-3)
sensitivity: 0.96 ng/mL
(MinDC+2SD; IGFBP-4)
sensitivity: 1.09 ng/mL
(MinDC+2SD; IGFBP-2)
sensitivity: 9.87 ng/mL
(MinDC+2SD; IGFBP-5)
standard curve range: 0.03-25 ng/mL
(IGFBP-1)
standard curve range: 0.07-50  ng/mL
( IGFBP-3)
standard curve range: 0.07-50 ng/mL
(IGFBP-7)
standard curve range: 0.14-100 ng/mL
(IGFBP-6)
standard curve range: 0.34-250 ng/mL
(IGFBP-2)
standard curve range: 0.69-500 ng/mL
(IGFBP-4)
standard curve range: 1.37-1000 ng/mL
(IGFBP-5)
inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-1)
inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-2)
inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-3)
inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-4)
inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-5)
inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-6)
inter-assay cv: <15%
intra-assay cv: <10%
(IGFBP-7)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

Related Categories

General description

Insulin-like growth factor (IGF) binding proteins (IGFBP) are expressed by multiple tissues and cells, including hepatic cells. By binding both IGF-1 and IGF-2, IGFBPs play a critical role in the regulation of IGF action, altering IGF interaction with cell surface receptors and increasing circulating IGF half-life and bioavailability. While their functions at the cellular level are not fully understood, studies have demonstrated the capacity to both stimulate and inhibit IGF-1 activity, depending on the system involved and the IGFBP studied. The ability of IGFBPs to regulate cell sensitivity by inhibiting IGF signaling may function in the control of tumor cell growth.

The MILLIPLEX® Human IGF Binding Protein (IGFBP) Panel, is used for the simultaneous quantification of any or all of the following analytes in human serum, plasma, and cell culture conditioned-media samples: IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-6, and IGFBP-7. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Endocrine

Specificity

Cross Reactivty
There was no or negligible cross-reactivity between the antibodies for an analyte and any of the other analytes in this panel.

Application

  • Analytes: IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-6, IGFBP-7
  • Recommended Sample Type: Human serum, plasma, and cell culture conditioned-media
  • Recommended Sample Dilution: For serum and plasma samples, 25 μL per well of a 1:25 dilution should be used when IGFBP3 is not included in the assay. Use a 1:200 dilution when IGFBP3 is included in the assay. Tissue culture supernatants may be run undiluted or appropriately diluted with control medium.
  • Assay Run Time: Overnight (16-20 hours) at 2-8°C. For improved sensitivity for some analytes use a 2 hour incubation at room temperature (20-25°C).
  • Research Category: Metabolism
  • Research Subcategory: Metabolic Disorders

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Packaging

96 well plate
Everything you need in a single kit.

Storage and Stability

Recommended storage for kit components is 2 - 8°C.

Other Notes

Please contact Technical Service for linearity of dilution.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Pictograms

Skull and crossbonesEnvironment
GHS06,GHS09

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Sens. 1

WGK

WGK 3

Regulatory Information

新产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nasser M Al-Daghri et al.
Nutrition & diabetes, 8(1), 54-54 (2018-10-06)
Subjects with low vitamin D levels are at risk of cardiometabolic disease. The aim of this study was to identify novel serological markers linking vitamin D status with cardiometabolic profile in non-diabetic adults with obesity. For the discovery phase, we
Arcangelo Liso et al.
Oncotarget, 8(37), 60826-60840 (2017-10-06)
Fever plays a role in activating innate immunity while its relevance in activating adaptive immunity is less clear. Even brief exposure to elevated temperatures significantly impacts on the immunostimulatory capacity of dendritic cells (DCs), but the consequences on immune response
Monika Bilic et al.
Endocrine connections, 8(6), 745-753 (2019-05-10)
Fetal growth restriction is linked to adverse health outcomes and is prevalent in low- and middle-income countries; however, determinants of fetal growth are still poorly understood. The objectives were to determine the effect of prenatal vitamin D supplementation on the
Zaohuo Cheng et al.
Frontiers in aging neuroscience, 10, 414-414 (2019-01-09)
It is well known that Alzheimer's disease (AD) is one of the most common progressive neurodegenerative diseases; it begins gradually, and therefore no effective medicine is administered in the beginning. Thus, early diagnosis and prevention of AD are crucial. The
Francesca D'Addio et al.
Nature communications, 13(1), 684-684 (2022-02-05)
Loss of pancreatic beta cells is a central feature of type 1 (T1D) and type 2 (T2D) diabetes, but a therapeutic strategy to preserve beta cell mass remains to be established. Here we show that the death receptor TMEM219 is

Related Content

Multiplexing Tips & Tricks

UnEnhance research with MILLIPLEX® multiplexing tips, industry guidance, and one-day assays for limited lab time.

Multiplexing Metabolic Syndrome Biomarkers

Multiplex immunoassays save time and sample volume in metabolic syndrome research, providing comprehensive insights into related conditions.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service